For the quarter ending 2025-09-30, HRTX made $38,213K in revenue. -$17,494K in net income. Net profit margin of -45.78%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net product sales | 38,213 | 37,200 | 38,903 | 45,342* |
| Cost of product sales | 11,914 | 9,857 | 8,457 | 10,274* |
| Gross profit | 26,299 | 27,343 | 30,446 | 35,068* |
| Research and development | 3,470 | 2,934 | 2,279 | 3,288* |
| General and administrative | 13,980 | 14,471 | 12,702 | 16,278* |
| Sales and marketing | 12,942 | 11,575 | 12,311 | 14,169* |
| Total operating expenses | 30,392 | 28,980 | 27,292 | 33,735* |
| Gain from operations | -4,093 | -1,637 | 3,154 | 1,333* |
| Loss on debt extinguishment | -11,339 | - | - | - |
| Other expense, net | -2,063 | -744 | -519 | 108* |
| Interest expense | - | - | - | 1,508* |
| Interest income | - | - | - | 888* |
| Total other (expense) income, net | - | - | - | -513* |
| Net gain | -17,495 | -2,381 | 2,635 | 820 |
| Unrealized gain (loss) on short-term investments | 1 | -2 | -12 | - |
| Comprehensive gain | -17,494 | -2,383 | 2,623 | 820 |
| Basic EPS | -0.1 | -0.02 | 0.02 | 0.005 |
| Diluted EPS | -0.1 | -0.02 | 0.01 | 0.005 |
| Basic Average Shares | 170,348,000 | 154,020,000 | 153,490,000 | 152,068,000 |
| Diluted Average Shares | 170,348,000 | 154,020,000 | 196,921,000 | 152,068,000 |
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)